-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 9, Hutchison Pharmaceuticals and Epizyme announced their cooperation to conduct research, development, production and commercialization of TAZVERIK® in Greater China (including China, Hong Kong, Macau and Taiwan)
TAZVERIK® is an EZH2 methyltransferase inhibitor developed by Epizyme and has been approved by the US FDA for the treatment of certain epithelioid sarcoma (ES) patients and certain follicular lymphoma (FL) patients
According to the terms of the agreement, Hutchison Pharma will be responsible for the development and commercialization of TAZVERIK® in Greater China
Hutchison Medical plans to be responsible for the development and approval of TAZVERIK® for the treatment of various blood and solid tumors in its region, including epithelioid sarcoma, follicular lymphoma and diffuse large B-cell lymphoma (DLBCL)